[{"orgOrder":0,"company":"MediWound","sponsor":"Balance Medical","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Genfa Medica","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandins","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Bromelain enriched proteolytic enzymes","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Soroka Medical Cente","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"MWPC005","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Soroka Medical Cente","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Soroka Medical Cente"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic enzymes enriched in bromelain","moa":"Peptide hydrolase","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","graph1":"Oncology","graph2":"Preclinical","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched in Bromelain","moa":"Peptide hydrolase","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Proteolytic Enzymes Enriched In Bromelain","moa":"Peptide hydrolase","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0.20999999999999999,"dosageForm":"Topical","sponsorNew":"MediWound \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandin synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0.17999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"EX-02","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bromelain","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care AB","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"SWEDEN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ U.S. Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"3M Health Care","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"EX-02","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Podiatry","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"MiMedx","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Podiatry","graph2":"Preclinical","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"MediWound \/ MediWound","highestDevelopmentStatusID":"4","companyTruncated":"MediWound \/ MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Molnlycke Health Care","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MediWound \/ Molnlycke Health Care","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Molnlycke Health Care"},{"orgOrder":0,"company":"MediWound","sponsor":"EIC","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MediWound","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MediWound \/ EIC","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ EIC"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Anacaulase-bcdb","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Technology","graph2":"Approved","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by MediWound

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EscharEx is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in the advanced stages of clinical development for the venous leg ulcers.

                          Brand Name : EscharEx

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NexoBrid (anacaulase-bcdb) is a topical biological product that enzymatically removes nonviable burn tissue, approved for treating patients with deep partial- and/or full-thickness thermal burns.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 15, 2024

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, approved the treatment of severe burns.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          August 05, 2024

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will significantly advance the Company’s EscharEx (bromelain enriched proteolytic enzyme) development program for patients with diabetic foot ulcers.

                          Brand Name : EscharEx

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 16, 2024

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase II

                          Sponsor : EIC

                          Deal Size : $16.2 million

                          Deal Type : Funding

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Podiatry

                          Study Phase : Phase II

                          Sponsor : Molnlycke Health Care

                          Deal Size : $25.0 million

                          Deal Type : Private Placement

                          Details : The net proceeds to advance EscharEx (bromelain enriched proteolytic enzyme) pre-commercial activities & expedite the development for the treatment of patients with diabetic foot ulcers.

                          Brand Name : EscharEx

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 15, 2024

                          Lead Product(s) : Bromelain Enriched Proteolytic Enzyme

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase II

                          Sponsor : Molnlycke Health Care

                          Deal Size : $25.0 million

                          Deal Type : Private Placement

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NexoBrid (anacaulase-bcdb) is a topically administered biological product for enzymatically removing nonviable burn tissue, being studied in phase 3 trials for partial and full-thickness burns.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 09, 2024

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 13, 2023

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration aims for the promotion of NexoBrid (anacaulase-bcdb), a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in Germany, Austria, Belgium, the Netherlands and Luxemburg.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 08, 2023

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Recipient : PolyMedics Innovations

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds...

                          Brand Name : EscharEx

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 11, 2023

                          Lead Product(s) : EX-02

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase II

                          Recipient : 3M Health Care

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

                          Brand Name : NexoBrid

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 09, 2023

                          Lead Product(s) : Anacaulase-bcdb

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank